Valion Bio, Inc. (VBIO) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -16.90M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 6.70M USD | Research and Development Expense |
| Selling, general and administration | 10.20M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-16.90M | (m) | (m) | $6.70M | $10.20M | (m) |
| 2026-03-31 | $-12.15M | (m) | (m) | $4.65M | $7.50M | (m) |
| 2025-12-31 | $-7.90M | (m) | (m) | $3.13M | $4.77M | (m) |
| 2025-09-30 | $-7.41M | $482.00K | (m) | $2.18M | (m) | -1536.51% |
| 2025-06-30 | $-6.35M | $462.00K | (m) | $1.75M | (m) | -1375.32% |
| 2025-03-31 | $-5.69M | $516.00K | (m) | $1.39M | (m) | -1101.94% |
| 2024-12-31 | $-5.66M | $780.00K | (m) | $1.31M | (m) | -725.77% |
| 2024-09-30 | $-6.36M | $957.00K | (m) | $1.34M | (m) | -664.79% |
| 2024-06-30 | $-6.69M | $1.11M | (m) | $1.25M | (m) | -601.17% |
| 2024-03-31 | $-7.61M | $1.13M | (m) | $1.42M | (m) | -671.08% |
| 2023-12-31 | $-8.24M | $1.18M | (m) | $1.66M | (m) | -701.11% |
| 2023-09-30 | $-8.26M | $1.23M | (m) | $1.73M | (m) | -672.94% |
| 2023-06-30 | $-9.08M | $1.42M | (m) | $1.79M | (m) | -639.06% |
| 2023-03-31 | $-9.97M | $1.79M | (m) | $1.82M | (m) | -557.77% |
| 2022-12-31 | $-10.10M | $1.84M | (m) | $1.73M | (m) | -548.80% |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-6.82M | $1.36M | (m) | $1.08M | (m) | -500.51% |
| 2022-01-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-5.63M | $1.26M | (m) | $878.00K | (m) | -448.13% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |